This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint
by Zacks Equity Research
AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.
Novartis Gets Approval for Remicade Biosimilar in Europe
by Zacks Equity Research
Novartis' (NVS) Sandoz wins approval for a biosimilar version of Remicade in Europe, which should further strengthen its biosimilars portfolio.
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
by Zacks Equity Research
Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.
Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FDRR
Should PowerShares Dividend Achievers Portfolio (PFM) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for PFM
Will China Erase Birth Limits? Stocks & ETFs to Watch
by Sanghamitra Saha
Reports of a possible end to China's four-decade-old birth restriction may boost these stocks and ETFs.
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
by Zacks Equity Research
Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.
Why Is Johnson & Johnson (JNJ) Down 4.1% Since its Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
by Zacks Equity Research
Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.
Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.
Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?
by Zacks Equity Research
Both Merck and Pfizer reported upbeat first-quarter results on May 1
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
by Zacks Equity Research
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
Theravance Biopharma (TBPH) Q1 Loss Narrows, Sales Up Y/Y
by Zacks Equity Research
Theravance Biopharma (TBPH) reports narrower-than-expected loss in Q1. Revenues surge year over year on increasing sales of Vibativ and collaborative revenues.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.
Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.
Pfizer (PFE) Stock Falls on Q1 Sales Miss, Earnings Beat
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings but misses the same for revenues in the first quarter. It retains its previously issued guidance for 2018.
Is Fidelity Dividend ETF for Rising Rates (FDRR) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FDRR
Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.
AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains
by Zacks Equity Research
AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Bristol-Myers (BMY) Beats on Q1 Earnings, Opdivo Impresses
by Zacks Equity Research
Bristol-Myers (BMY) beats estimates on both counts in the first quarter. Eliquis and Opdivo record solid sales.
Should PowerShares Dividend Achievers Portfolio (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
Should OShares FTSE U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for OUSA
The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Honeywell, Morgan Stanley, Novartis and eBay
Top Research Reports for Johnson & Johnson, Honeywell & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Honeywell (HON) and Morgan Stanley (MS).